Lifebridge 10000

Lifebridge 10000

Early Stage

Because They Have More Life To Live - Breakthrough Cancer Therapy

Because They Have More Life To Live - Breakthrough Cancer Therapy


Raised to Date: Raised: $23,191

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Rolling Commitments ($USD)

Reporting Date


Days Remaining
% of Min. Goal
% of Max. Goal
Likelihood of Max
Avg. Daily Raise


# of Investors


Create a free account today to gain access to KingsCrowd analytics.
Year Founded



Healthcare & Pharmaceuticals

Tech Sector



Longwood, Florida

Cancer. It’s not just a pervasive disease -- it’s a pervasive life norm. Athletes wear pink ribbons for breast cancer awareness. Children and grandparents alike walk in Relays for Life. Cancer is one of the few unifying forces in this divided world, because at the end of the day, we are all impacted by it, and we all feel the same - let’s beat it.

Right now, Tumor Treating Fields (TTF) is a therapy found very successful in helping us win that battle against solid tumor cancer However, that is only true for when patients have one solid tumor cancer. When a late-stage cancer patients presents with metastatic disease in two or more locations on the body at once, TTF cannot treat both of those areas at once. The patient must make the painful decision of which cancer to treat...and which cancer to let grow.

That’s where Lifebridge 10,000 comes into play and as the anti-cancer, pro-TTF white knight. Inspired by Laurie, CEO Peter Travers’ wife, Lifebridge 10,000 has built and successfully tested a patent-pending prototype that would allow TTF to treat multiple cancers at once in that type of situation. Laurie was forced to make the choice of which cancer to fight and which cancer to leave, and Peter wants to make sure that cancer patients using TTF will not have to make that decision ever again.

A percentage of profits will be given to patients who cannot afford treatment. LifeBridge will also sell their therapy on a sliding scale, with those less fortunate given significant discounts. Sadly, the market for this device is strong, and the demand is high. WHO predicts a 65% growth in the number of new cancer patients over the next 15 years, and pharmaceutical companies are jumping on board with TTF - Pfizer, Johnson and Johnson, and other firms have raised over $250,000,000 to make TTF the accepted 4th modality for cancer treatment.

The bottom line is that investing in Lifebridge 10,000 could mean that you’ll get a doubly high return - your profit means that you’re helping to beat cancer.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Lifebridge 10000 01/13/2022 Wefunder $25,000,000 $166,578 SAFE Funded RegCF
Lifebridge 10000 03/27/2018 StartEngine $12,135,235 $23,191 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Lifebridge 10000 on Start Engine
Platform: StartEngine
Security Type: Equity - Common
Valuation: $12,135,235
Price per Share: $1.00

Follow company

Follow Lifebridge 10000 on Start Engine

Buy Lifebridge 10000's Deal Report

Warning: according to the close date for this deal, Lifebridge 10000 may no longer be accepting investments.

Lifebridge 10000 Deal Report

Get KingsCrowd’s comprehensive report on Lifebridge 10000 including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Lifebridge 10000 is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Lifebridge 10000 deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge